Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.

Hepatology (Baltimore, Md.) - 1 Jul 2002

Papatheodoridis George V, Dimou Evangelini, Laras Andreas, Papadimitropoulos Vassilios, Hadziyannis Stephanos J

Abstract excerpt

We studied the course of virologic breakthroughs detected by a quantitative polymerase chain reaction (PCR) assay in 32 of 78 patients with hepatitis B e antigen (HBeAg)-negative precore mutant hepatitis B virus (HBV) chronic liver disease under long-term lamivudine monotherapy. Serum HBV DNA levels were measured every 3 months and on every biochemical breakthrough. YMDD mutants were detected in 30 of the 32...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Lamivudine

Share to Recurrence

Share to Remission Induction

Share to Viremia

Source

Identifiers

PMID: 12085368
DOI: 10.1053/jhep.2002.33894

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.PMID 12085368Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants.Semantic proximity Read ↗

Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Semantic proximity Read ↗

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.Semantic proximity Read ↗

Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.Semantic proximity Read ↗

Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B.Semantic proximity Read ↗

Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.Semantic proximity Read ↗

Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.Semantic proximity Read ↗

Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.Semantic proximity Read ↗

Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.Semantic proximity Read ↗

Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.